相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Selective and mixed endothelin receptor antagonism in cardiovascular disease
Neeraj Dhaun et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Felix Boehm et al.
CARDIOVASCULAR RESEARCH (2007)
Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis
Tuomas O. Peltonen et al.
CIRCULATION (2007)
Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves
Satu Helske et al.
EUROPEAN HEART JOURNAL (2007)
Regulation of the mammalian heart function by nitric oxide
PB Massion et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY (2005)
Spectrum of calcific aortic valve disease - Pathogenesis, disease progression, and treatment strategies
RV Freeman et al.
CIRCULATION (2005)
Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice
LL Yang et al.
CIRCULATION (2004)
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial
I Anand et al.
LANCET (2004)
Mechanisms of aortic valve calcification
ER Mohler
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure
J Bergler-Klein et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2004)
Induction of local angiotensin II-producing systems in stenotic aortic valves
S Helske et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells
SY Wu et al.
PEPTIDES (2003)
Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis
Y Soini et al.
HUMAN PATHOLOGY (2003)
Augmented endothelial uptake of oxidized low-density lipoprotein, in response to endothelin-1
H Morawietz et al.
CLINICAL SCIENCE (2002)
Endothelins and endothelin receptor antagonists -: Therapeutic considerations for a novel class of cardiovascular drugs
TF Lüscher et al.
CIRCULATION (2000)